Bone marrow transplantation in sickle cell anemia

Area of Science:

• Hematology
• Transplant Immunology
• Genetic Blood Disorders

Background:

• Sickle cell disease (SCD) is a debilitating inherited blood disorder with significant long-term complications.
• Hematopoietic cell transplantation (HCT) presents a potential cure for SCD, building on successful applications in beta-thalassemia major.
• Current event-free survival after matched sibling HCT for SCD is 82%, but complications remain a barrier.

Purpose of the Study:

• To review the current status and future directions of HCT for sickle cell disease.
• To highlight advancements in conditioning regimens and alternative stem cell sources.
• To address the challenges of transplant-related complications in SCD.

Main Methods:

• Review of existing literature on HCT for SCD.
• Analysis of outcomes and complications associated with HCT in SCD patients.
• Discussion of novel conditioning strategies and alternative stem cell sources.

Main Results:

• Allogeneic-matched sibling HCT for SCD demonstrates an 82% event-free survival rate.
• Transplant-related complications are significant barriers, especially for older patients.
• Novel conditioning regimens and alternative stem cell sources show promise for improving HCT applicability.

Conclusions:

• HCT is a viable curative option for selected SCD patients.
• Minimizing transplant toxicity through novel regimens is crucial for wider HCT application.
• Expanding stem cell sources can increase HCT accessibility for the SCD population.